alexa Cancer of Unknown Primary Site: Not All is Lost!
ISSN: 2376-0311

JBR Journal of Clinical Diagnosis and Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Cancer of Unknown Primary Site: Not All is Lost!

Muhammad Furrukh*, Ikram Burney, Asim Qureshi and Ritu Lakhtakia

Department of Oncology, Shifa International Hospital, Pakistan

*Corresponding Author:
Muhammad Furrukh
Department of Oncology
Shifa International Hospital
Islamabad, Pakistan
Tel: 0092 310 3335889
E-mail: [email protected]

Received Date: November 24, 2014; Accepted Date: December 19, 2014; Published Date: December 26, 2014

Citation: Furrukh M, Burney I, Qureshi A, Lakhtakia R (2015) Cancer of Unknown Primary Site: Not All is Lost!. J Clin Diagn Res 3:115. doi:10.4172/2376-0311.1000115

Copyright: ©2015 Furrukh M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

A Cancer of Unknown Primary Site (CUPS) is defined as a metastatic tumor for which the site of origin remains unknown after establishing tissue diagnosis despite a standard diagnostic approach. It is still not known whether CUP is an entity with dormancy of primary as its hallmark or a distinct entity with specific genetic aberrations which define it as a primary metastatic disease. It poses a diagnostic challenge to the pathologists and often poses a therapeutic dilemma for the oncologists. The diagnostic algorithm includes; age, gender, histology, site of metastasis, distribution and natural history of disease, and expression of tissue specific markers by the malignant clones as revealed on immunostains, e.g. TTF1 for thyroid gland and adenocarcinoma lung, PSA for prostate gland, estrogen/ progesterone receptors and gross cystic disease fluid protein-15 for breast cancer, etc. Despite extensive and expensive diagnostic work up, in almost 20-45% cases the site of their origin remains unknown, however the yield rises to 70-80% after postmortem examination. While the pathology teams are working to resolve the primary site, the oncology teams are adamant on identifying subset of patients that may be treatable and potentially curable. However, CUPS remains aggressive, and generally associated with a poorer prognosis with a median survival of less than a year. The review focuses on current practices in diagnoses and treatment of an occasionally rare, and a challenging entity.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords